IRIDEX Earnings Call Transcripts
Fiscal Year 2026
-
IRIDEX highlighted its transformation in laser-based eye care, strong global presence, and broad product portfolio for retina and glaucoma. Achieving profitability in Q4 2025, the company emphasized clinical advantages of MicroPulse technology and operational efficiencies driving sustained growth.
-
Q1 2026 revenue was $11.8M, flat year-over-year, with strong G6 probe growth offsetting weaker Retina sales due to international headwinds. Cost reduction and manufacturing initiatives are on track, and 2026 guidance of $51–$53M revenue and positive cash flow is reaffirmed.
Fiscal Year 2025
-
Revenue grew 8% to $52.7M in 2025 with strong Q4 growth and positive adjusted EBITDA. Cost reductions and operational streamlining led to positive cash flow, while 2026 guidance projects 1–5% growth excluding Middle East sales.
-
The company is leveraging innovative laser technologies and strong clinical data to expand in both retina and glaucoma markets, with a focus on operational efficiency and margin improvement. Recent cost reductions, product launches, and a robust replacement cycle support a positive financial outlook.
-
Third quarter revenue grew 8% year-over-year to $12.5 million, with improved Adjusted EBITDA and reduced operating expenses. Gross margin was impacted by a one-time inventory write-down, but underlying profitability and cash flow trends remain positive.
-
Q2 2025 saw 7% year-over-year and 14% sequential revenue growth, reduced operating expenses by 28%, and positive adjusted EBITDA. Strong Pascal system sales drove retina segment growth, while cost controls and operational efficiencies improved financial health.
-
Revenue grew to $11.9M in Q1 2025, with positive adjusted EBITDA and improved gross margin. Cost reductions and a $10M investment strengthened the balance sheet, while growth in glaucoma products offset a slight retina revenue decline.
-
Recent cost reductions have led to positive adjusted EBITDA and improved cash flow, with continued revenue growth in both retina and glaucoma segments. A $10 million strategic investment from Novel Inspiration supports operational improvements, potential acquisitions, and a focus on long-term value creation.
Fiscal Year 2024
-
Q4 2024 saw revenue growth, improved gross margin, and positive adjusted EBITDA, driven by cost reductions and a strategic $10M investment from Novel Innovations. Glaucoma product sales rose, while retina sales dipped slightly. Industry M&A and LCD changes shape a positive 2025 outlook.
-
Leadership transition and cost-cutting have accelerated the strategic review, with Q4 expected to be EBITDA positive. Q3 revenue declined 10% year-over-year, but glaucoma product sales grew and regulatory changes are set to boost future adoption.
-
Q2 2024 revenue was $12.6M, up 7% sequentially, with recovery in both retina and glaucoma segments. Gross margin declined to 40.7%, and net loss narrowed to $2.7M. Strategic review and recent $3.4M financing aim to support growth and a potential transaction this year.